A nationwide study on parathyroid carcinoma

References

• De Quervain F. Parastruma maligna aberata. 1904;100:334–352.
   Google Scholar
• Wei CH, Harari A. Parathyroid carcinoma: update and guidelines for management. Curr Treat Options Oncol. 2012;13:11–23.
   PubMed Web of Science ®Google Scholar
• Sharretts JM, Kebebew E, Simonds WF. Parathyroid cancer. Semin Oncol. 2010;37:580–590.
   PubMed Web of Science ®Google Scholar
• Schulte KM, Talat N. Diagnosis and management of parathyroid cancer. Nat Rev Endocrinol. 2012;8:612–622.
   PubMed Web of Science ®Google Scholar
• Marcocci C, Cetani F, Rubin MR, et al. Parathyroid carcinoma. J Bone Miner Res. 2008;23:1869–1880.
   PubMed Web of Science ®Google Scholar
• Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–1741.
   PubMed Web of Science ®Google Scholar
• Brown S, O'neill C, Suliburk J, et al. Parathyroid carcinoma: increasing incidence and changing presentation. ANZ J Surg. 2011;81:528–532.
   PubMed Web of Science ®Google Scholar
• Bondeson L, Grimelius L, DeLellis RA, et al. Parathyroid carcinoma and Parathyroid adenoma. In: DeLellis RA, Lloyd RV, Heitz P, et al., editors. Pathology and genetics. tumors of endocrine organs. WHO Classification of Tumours. Lyon: IARC Press; 2004. p. 124–131.
   Google Scholar
• Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–2174.
   PubMed Web of Science ®Google Scholar
• Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–3686.
   PubMed Web of Science ®Google Scholar
• Tan MH, Morrison C, Wang P, et al. Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin Cancer Res. 2004;10:6629–6637.
   PubMed Web of Science ®Google Scholar
• Quinn CE, Healy J, Lebastchi AH, et al. Modern experience with aggressive parathyroid tumors in a high-volume New England referral center. J Am Coll Surg. 2015;220:1054–1062.
   PubMed Web of Science ®Google Scholar
• Ippolito G, Palazzo FF, Sebag F, et al. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br J Surg. 2007;94:566–570.
   PubMed Web of Science ®Google Scholar
• Howell VM, Haven CJ, Kahnoski K, et al. HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J Med Genet. 2003;40:657–663.
   PubMed Web of Science ®Google Scholar
• Cetani F, Ambrogini E, Viacava P, et al. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur J Endocrinol. 2007;156:547–554.
   PubMed Web of Science ®Google Scholar
• Cetani F, Banti C, Pardi E, et al. CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer. Endocr Connect. 2013;2:186–195.
   PubMed Web of Science ®Google Scholar
• Juhlin CC, Villablanca A, Sandelin K, et al. Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification. Endocr Relat Cancer. 2007;14:501–512.
   PubMed Web of Science ®Google Scholar
• Shattuck TM, Valimaki S, Obara T, et al. Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N Engl J Med. 2003;349:1722–1729.
   PubMed Web of Science ®Google Scholar
• Schulte KM, Talat N, Galata G, et al. Oncologic resection achieving r0 margins improves disease-free survival in parathyroid cancer. Ann Surg Oncol. 2014;21:1891–1897.
   PubMed Web of Science ®Google Scholar
• Cetani F, Pardi E, Marcocci C. Update on parathyroid carcinoma. J Endocrinol Invest. 2016;39:595–606.
   PubMed Web of Science ®Google Scholar
• Kebebew E, Arici C, Duh QY, et al. Localization and reoperation results for persistent and recurrent parathyroid carcinoma. Arch Surg. 2001;136:878–885.
   PubMedGoogle Scholar
• Sadler C, Gow KW, Beierle EA, et al. Parathyroid carcinoma in more than 1000 patients: a population-level analysis. Surgery. 2014;156:1622–1629; discussion 1629-–630.
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, et al. Two hundred eighty-six cases of parathyroid carcinoma treated in the U.S. between 1985-1995: a National Cancer Data Base Report. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1999;86:538–544.
   PubMed Web of Science ®Google Scholar
• Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22:3990–3995.
   PubMed Web of Science ®Google Scholar
• Korpi-Hyövälti E, Cranston T, Ryhänen E, et al. CDC73 intragenic deletion in familial primary hyperparathyroidism associated with parathyroid carcinoma. J Clin Endocrinol Metab. 2014;99:3044–3048.
   PubMed Web of Science ®Google Scholar
• Huopio H, Miettinen PJ, Ilonen J, et al. Clinical, genetic, and biochemical characteristics of early-onset diabetes in the Finnish population. J Clin Endocrinol Metab. 2016;101:3018–3026.
   PubMed Web of Science ®Google Scholar
• Tuominen VJ, Ruotoistenmäki S, Viitanen A, et al. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res. 2010;12:R56.
   PubMed Web of Science ®Google Scholar
• Kim HK, Oh YL, Kim SH, et al. Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma. Head Neck. 2012;34:201–206.
   PubMed Web of Science ®Google Scholar
• Villar-del-Moral J, Jimenez-Garcia A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156:1132–1144.
   PubMed Web of Science ®Google Scholar
• Witteveen JE, Hamdy NA, Dekkers OM, et al. Downregulation of CASR expression and global loss of parafibromin staining are strong negative determinants of prognosis in parathyroid carcinoma. Mod Pathol. 2011;24:688–697.
   PubMed Web of Science ®Google Scholar
• Truran PP, Johnson SJ, Bliss RD, et al. Parafibromin, galectin-3, PGP9.5, Ki67, and cyclin D1: using an immunohistochemical panel to aid in the diagnosis of parathyroid cancer. World J Surg. 2014;38:2845–2854.
   PubMed Web of Science ®Google Scholar
• Howell VM, Gill A, Clarkson A, et al. Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J Clin Endocrinol Metab. 2009;94:434–441.
   PubMed Web of Science ®Google Scholar
• Kruijff S, Sidhu SB, Sywak MS, et al. Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas. Ann Surg Oncol. 2014;21:426–433.
   PubMed Web of Science ®Google Scholar
• Abbona GC, Papotti M, Gasparri G, et al. Proliferative activity in parathyroid tumors as detected by Ki-67 immunostaining. Hum Pathol. 1995;26:135–138.
   PubMed Web of Science ®Google Scholar
• Arvai K, Nagy K, Barti-Juhasz H, et al. Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma. Pathol Oncol Res. 2012;18:607–614.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ranvier GG, Khanafshar E, Tacha D, et al. Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer. 2009;115:334–344.
   PubMed Web of Science ®Google Scholar
• Farnebo F, Auer G, Farnebo LO, et al. Evaluation of retinoblastoma and Ki-67 immunostaining as diagnostic markers of benign and malignant parathyroid disease. World J Surg. 1999;23:68–74.
   PubMed Web of Science ®Google Scholar
• Lloyd RV, Carney JA, Ferreiro JA, et al. Immunohistochemical analysis of the cell cycle-associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas. Endocr Pathol. 1995;6:279–287.
   PubMed Web of Science ®Google Scholar
• Wang O, Wang C, Nie M, et al. Novel HRPT2/CDC73 gene mutations and loss of expression of parafibromin in Chinese patients with clinically sporadic parathyroid carcinomas. PLoS One. 2012;7:e45567.
   PubMed Web of Science ®Google Scholar
• Fernandez-Ranvier GG, Khanafshar E, Jensen K, et al. Parathyroid carcinoma, atypical parathyroid adenoma, or parathyromatosis. Cancer. 2007;110:255–264.
   PubMed Web of Science ®Google Scholar
• Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–726.
   PubMed Web of Science ®Google Scholar
• Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–731.
   PubMed Web of Science ®Google Scholar
• Schulte KM, Gill AJ, Barczynski M, et al. Classification of parathyroid cancer. Ann Surg Oncol. 2012;19:2620–2628.
   PubMed Web of Science ®Google Scholar